Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia

BACKGROUND: Eradication of minimal residual disease (MRD), at the end of Fludarabine-Cyclophosphamide-Rituximab (FCR) treatment, is a validated surrogate marker for progression-free and overall survival in chronic lymphocytic leukaemia. But such deep responses are also associated with severe immuno-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Gauthier, Martin, Durrieu, Françoise, Martin, Elodie, Peres, Michael, Vergez, François, Filleron, Thomas, Obéric, Lucie, Bijou, Fontanet, Quillet Mary, Anne, Ysebaert, Loic
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6694602/
https://ncbi.nlm.nih.gov/pubmed/31412798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5971-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados